MPDL3280A receives second breakthrough therapy designation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA granted a second breakthrough designation to the immunotherapy MPDL3280A (anti-PDL1).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Login